Research Paper Volume 12, Issue 22 pp 23096—23113

Protective effect of DLX6-AS1 silencing against cerebral ischemia/reperfusion induced impairments

Figure 6. BOK may be a target of miR-149-3p. (A) The predicted binding sites of miR-149-3p and BOK by TargetScanVert. (B) BOK expression in the brain I/R model treated by LV-DLX6-AS1. (CE) BOK protein expression following treatment with a DLX6-AS1 shRNA, miR-149-3p mimic or miR-149-3p inhibitor in N2a cells. (F) Representative images and statistics of TUNEL staining of N2a cells used to confirm apoptotic changes (100X). (G) Cleaved caspase-3 protein levels measured by western blotting. Values represent mean ± SEM (n = 3 in each group). **P < 0.01 vs Ctrl, ***P < 0.001 vs Ctrl or Sham or NEG; +P < 0.05 vs IS 1 h/R 24 h + LV-NEG or OGD 3 h/R 24 h + NEG,++P < 0 .01 vs OGD 3 h/R 24 h + NEG-mimic or OGD 3 h/R 24 h + NEG-siRNA, +++P < 0.001 vs OGD 3 h/R 24 h + NEG-siRNA; #P < 0.05 vs OGD 3 h/R 24 h + NEG or OGD 3 h/R 24 h + DLX6-AS1-shRNA.